Omeros’ Transplant Drug Sales Rise 26% From Second Quarter As Adjusted Income Improves
A $62.0 million non-cash valuation loss pushed reported results into the red, even as Omeros generated cash from operations.
Omeros, which sells YARTEMLEA for a potentially fatal stem cell transplant complication, grew the drug’s third-quarter net sales 26% to $35.9 million from $28.5 million in the second quarter, according to its Monday SEC filing. Adjusted net income increased to $4.7 million from $1.8 million, but a $62.0 million non-cash valuation loss pushed reported results into the red.
Sales Growth Meets A Valuation Loss
Omeros reported a quarterly loss of $57.4 million, or $0.79 per share, compared with second-quarter income of $13.2 million, or $0.18 per share. The non-cash loss came primarily from revaluing a financial instrument attached to notes due in 2029 that can convert into shares.
Excluding non-cash valuation changes, adjusted net income was $0.06 per share, up from $0.02 in the second quarter. Operating income rose to $4.5 million from $0.1 million, while combined research, development, selling and administrative spending increased to approximately $30.6 million from $27.7 million.
Gross drug sales reached $41.8 million, versus $32.2 million in the second quarter. Deductions from gross revenue increased to 14.0% from 11.5%, which Omeros attributed to more purchases under the 340B Drug Pricing Program as outpatient use and its customer base expanded.
Omeros Chairman and CEO Gregory A. Demopulos said, “That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.”
Cash Generation And Fewer Convertible Shares
Omeros generated $13.3 million of operating cash flow in the third quarter, its consecutive quarter of positive cash generation. It ended the quarter with $95.3 million in cash and short-term investments.
Debt repurchases completed in July removed approximately 4.9 million potentially issuable shares, reducing the shares available through conversion from 11.4 million to 6.5 million. Omeros paid $60.2 million, plus $0.2 million of accrued interest, to retire $30.5 million of principal, leaving approximately $40.3 million outstanding and eliminating $8.6 million in scheduled interest payments.
Including more than 843,000 common shares repurchased at an average $11.70 per share in the first half of 2026, Omeros has reduced outstanding or potentially issuable shares by approximately 5.8 million this year.
Another potential funding source is the zaltenibart antibody program Novo Nordisk bought in 2025. Omeros remains eligible for more than $1.8 billion in development and commercial milestones, including up to $100 million in near-term payments, plus royalties.
Transplant Access And New Trials
YARTEMLEA treats transplant-associated thrombotic microangiopathy, or TA-TMA, in adults and children aged two and older. U.S. sales began in January 2026 following FDA approval on December 23, 2025; Omeros sells the drug through its own team working with transplant centers.
Europe remains a regulatory obstacle. European Medicines Agency reviewers reaffirmed their negative opinion on narsoplimab in October after reconsidering the June decision.
Omeros anticipates studies of YARTEMLEA in acute respiratory distress syndrome and prevention of TA-TMA in high-risk pediatric transplant patients in late 2026 or early 2027. Each study targets approximately 50 to 60 participants and will compare treated patients with historical controls.
The company expects enrollment in its OMS527 cocaine-use-disorder trial in the first quarter of 2027. Development for that indication is fully funded by the National Institute on Drug Abuse; Omeros is conducting an additional nonclinical study requested by the FDA.
Omeros also targets late 2027 for the first human trial of OMS805, its acute myeloid leukemia drug candidate.
Sources
- 8-K Filing — OMEROS CORP (OMER) — SEC EDGAR
- Exhibit ex_1011405.htm — OMEROS CORP 8-K exhibit — SEC EDGAR
- Omeros Corporation Reports Third Quarter 2026 Financial Results — businesswire.com
- Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026 — businesswire.com